JP2023551980A5 - - Google Patents

Info

Publication number
JP2023551980A5
JP2023551980A5 JP2023534290A JP2023534290A JP2023551980A5 JP 2023551980 A5 JP2023551980 A5 JP 2023551980A5 JP 2023534290 A JP2023534290 A JP 2023534290A JP 2023534290 A JP2023534290 A JP 2023534290A JP 2023551980 A5 JP2023551980 A5 JP 2023551980A5
Authority
JP
Japan
Prior art keywords
cancer
product according
pharmaceutical product
subject
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023534290A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551980A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/084659 external-priority patent/WO2022122765A2/en
Publication of JP2023551980A publication Critical patent/JP2023551980A/ja
Publication of JP2023551980A5 publication Critical patent/JP2023551980A5/ja
Pending legal-status Critical Current

Links

JP2023534290A 2020-12-07 2021-12-07 抗体およびタキソンの併用療法 Pending JP2023551980A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063122042P 2020-12-07 2020-12-07
US63/122,042 2020-12-07
PCT/EP2021/084659 WO2022122765A2 (en) 2020-12-07 2021-12-07 Antibody and taxane combination therapy

Publications (2)

Publication Number Publication Date
JP2023551980A JP2023551980A (ja) 2023-12-13
JP2023551980A5 true JP2023551980A5 (cg-RX-API-DMAC7.html) 2024-12-13

Family

ID=79165020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023534290A Pending JP2023551980A (ja) 2020-12-07 2021-12-07 抗体およびタキソンの併用療法

Country Status (11)

Country Link
US (1) US20240109972A1 (cg-RX-API-DMAC7.html)
EP (1) EP4255575A2 (cg-RX-API-DMAC7.html)
JP (1) JP2023551980A (cg-RX-API-DMAC7.html)
KR (1) KR20230128482A (cg-RX-API-DMAC7.html)
CN (1) CN117083080A (cg-RX-API-DMAC7.html)
AU (1) AU2021393908A1 (cg-RX-API-DMAC7.html)
CA (1) CA3200895A1 (cg-RX-API-DMAC7.html)
IL (1) IL303424A (cg-RX-API-DMAC7.html)
MX (1) MX2023006404A (cg-RX-API-DMAC7.html)
TW (1) TW202237081A (cg-RX-API-DMAC7.html)
WO (1) WO2022122765A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250020679A (ko) 2017-08-04 2025-02-11 젠맵 에이/에스 Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
EP4558168A4 (en) * 2022-07-20 2026-07-15 Biontech Us Inc POLYTHERAPY INCLUDING A NEOANTIGEN-BASED VACCINE
EP4751731A1 (en) * 2024-11-29 2026-06-03 Affimed GmbH Combination of a bispecific antibody construct, an immune checkpoint inhibitor and a taxane

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 1가 항체 및 그의 제조 방법
KR100745488B1 (ko) * 2006-07-04 2007-08-02 학교법인 울산공업학원 항-4-1bb 항체 및 화학 항암제를 포함하는 암 질환 예방및 치료용 약학 조성물
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
ES2763429T5 (es) * 2013-12-17 2023-06-21 Hoffmann La Roche Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos
SMT201900702T1 (it) 2015-01-08 2020-01-14 Genmab As Agenti agonistici leganti il recettore del tnf
KR20250020679A (ko) * 2017-08-04 2025-02-11 젠맵 에이/에스 Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
SG11202105152YA (en) * 2018-11-30 2021-06-29 Abl Bio Inc Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
EP3897612A1 (en) * 2018-12-19 2021-10-27 Genentech, Inc. Treatment of breast cancer using combination therapies comprising an akt inhibitor, a taxane, and a pd-l1 inhibitor

Similar Documents

Publication Publication Date Title
TWI795347B (zh) 使用抗pd-1抗體與抗ctla-4抗體之組合以治療肺癌
CA2715166C (en) Monoclonal antibodies for tumor treatment
TWI908743B (zh) 抗dll3藥劑之給藥方案
JP2024525758A5 (cg-RX-API-DMAC7.html)
WO2023061472A1 (zh) 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途
JP2022541591A5 (cg-RX-API-DMAC7.html)
WO2023077099A1 (en) Cancer specific plectin-1 specific antibodies and methods of use thereof
CN121079315A (zh) 用于组合疗法的方法和组合物
CN119587691A (zh) 抗her2抗体药物偶联物联合抗her2抗体治疗肿瘤
CN120344271A (zh) 抗her2抗体药物偶联物治疗乳腺癌
JP2024536383A5 (cg-RX-API-DMAC7.html)
US20220211846A1 (en) Abt-165 in combination with folinic acid, 5-fluorouracil, and irinotecan for the treatment of cancers
KR20240038008A (ko) 암 치료 방법 및 조성물
TW202545570A (zh) 抗體藥物偶聯物和免疫檢查點抑制劑的聯合應用
WO2025082449A1 (zh) 抗体药物偶联物和免疫检查点抑制剂的联合应用
JP2024523438A5 (cg-RX-API-DMAC7.html)
JP2024538755A5 (cg-RX-API-DMAC7.html)
JP2024502465A5 (cg-RX-API-DMAC7.html)
AU2020410527A1 (en) Treatment with site specific HER2 antibody-drug conjugates
WO2026021442A1 (zh) 抗体药物偶联物在制备治疗肺癌的药物中的用途
KR20200105825A (ko) 삼중 음성 유방암의 치료를 위한 pd-1 항체 및 아파티닙의 조합 치료의 용도
WO2026077321A1 (zh) 抗her2抗体药物偶联物和免疫检查点抑制剂的药物组合
WO2025252203A1 (zh) 抗Nectin-4抗体药物偶联物治疗肿瘤的用途
WO2024177899A1 (en) Methods for treating non-small cell lung cancer with anti-pd-1 antibodies
EP4694894A1 (en) Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor